Low Incidence of Local Recurrence When Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer
Findings from the LUMINA study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
Panitumumab Added to Infusional Fluorouracil Plus Leucovorin May Be a Reasonable Initial Treatment Option for Elderly Patients with RAS/BRAF wild-type mCRC
Findings from the PANDA study
FDA Approves Trifluridine and Tipiracil with Bevacizumab for Previously Treated Metastatic Colorectal Cancer
Evidence for efficacy is based on the results from the SUNLIGHT study
EMA Recommends Granting a Conditional Marketing Authorisation for Epcoritamab
It is indicated for the treatment of adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy
Long-Term Efficacy of Single-Agent Neoadjuvant/Adjuvant PD1 Blockade for Resectable Cutaneous Melanoma in Patients with a pCR
Findings from the longest follow-up of a neoadjuvant study in this setting
Zolbetuximab plus CAPOX Prolongs Survival in CLDN18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastro-oesophageal Junction Adenocarcinoma
Findings from the GLOW study
A Positive Trend in OS Improvement Favours Atezolizumab Compared to Best Supportive Care in Stage II-IIIA Resected NSCLC, Primarily Driven by the PD-L1 TC ≥50% Subgroup
Findings from the IMpower010 study
FDA Approves Dostarlimab-gxly with Chemotherapy for Endometrial Cancer
Evidence for efficacy is based on the results from the RUBY study
EMA Recommends Granting a Conditional Marketing Authorisation for Talquetamab
It is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma
Adjuvant Everolimus Does Not Improve Recurrence-Free Survival Among Patients with Renal Cell Carcinoma
Findings from the EVEREST study
Niraparib Plus Abiraterone Acetate and Prednisone Improves rPFS and Other Clinically Relevant Outcomes in First-Line Treatment for Patients with mCRPC
Findings from the MAGNITUDE study
HER2 Expression is a Determinant of Sensitivity to Trastuzumab Deruxtecan in Metastatic Breast Cancer, Although Other Mechanisms May Be Involved
Findings from the DAISY study